Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...